Axsome Therapeutics (AXSM) Non-Current Debt (2015 - 2026)

Axsome Therapeutics (AXSM) has 12 years of Non-Current Debt data on file, last reported at $117.8 million in Q1 2026.

• For the quarter ending Q1 2026, Non-Current Debt fell 35.02% year-over-year to $117.8 million; the trailing twelve-month figure through Mar 2026 stood at $117.8 million (down 35.02% YoY), and the FY2025 full-year result was $117.7 million, down 34.84% from the prior year.
• Non-Current Debt was little changed at $117.8 million in Q1 2026, from $117.7 million in the prior quarter.
• In the past five years, Non-Current Debt ranged from a high of $181.4 million in Q1 2025 to a low of $49.3 million in Q1 2022.
• A 5-year average of $134.2 million and a median of $117.8 million in 2026 frame the typical range for Non-Current Debt.
• Across the five-year window, Non-Current Debt soared 199.35% in 2023 and tumbled 54.92% in 2024, its largest moves.
• Tracing AXSM's Non-Current Debt over 5 years: stood at $94.3 million in 2022, then soared by 88.92% to $178.1 million in 2023, then increased by 1.48% to $180.7 million in 2024, then sank by 34.84% to $117.7 million in 2025, then gained by 0.09% to $117.8 million in 2026.
• Business Quant data shows AXSM's Non-Current Debt at $117.8 million in Q1 2026, $117.7 million in Q4 2025, and $117.6 million in Q3 2025.